GlassScriptPhysician profile
Neil J Atodaria
NPI 1619933363
$2,938.75
in general payments reported to CMS, 2019-2025
16 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $143 · 2021: $312 · 2022: $676 · 2023: $274 · 2024: $525 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $652.15 | 2022-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $556.87 | 2022-2025 | Voyager Dslt, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $475.82 | 2022-2025 | Durysta |
| New World Medical,INC. | $295.20 | 2023-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Aerie Pharmaceuticals, INC. | $229.97 | 2019-2021 | |
| Sight Sciences, INC. | $184.80 | 2020-2025 | Omni Surgical System |
| Allergan, INC. | $169.80 | 2020-2021 | |
| Rxsight INC | $124.13 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $122.96 | 2022-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $40.85 | 2019 | |
| Sun Pharmaceutical Industries INC. | $37.47 | 2019-2023 | Bromsite, Xelpros, Cequa |
| Johnson & Johnson Surgical Vision, INC. | $17.27 | 2023 | |
| Bausch & Lomb Americas INC. | $17.00 | 2024 | Vyzulta |
| Eyepoint US, INC. | $14.46 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Atodaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.